Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Vaxart ( (VXRT) ) has shared an announcement.
On December 18, 2025, Vaxart, Inc. entered into a termination agreement with Britannia Pointe Grand Limited Partnership to end its lease for approximately 24,606 square feet of office and lab space at 170 Harbor Way in South San Francisco, which has served as the company’s headquarters. The lease, originally set to expire on March 31, 2029, will now terminate effective May 15, 2026, with Vaxart obligated only to pay rent and reimbursable expenses through the termination date and incurring no termination fees or penalties, as part of broader cost‑reduction efforts. Concurrent with the lease termination, Vaxart plans to relocate its headquarters and labs to one of its other offices in the South San Francisco area, indicating a consolidation of its facilities footprint while maintaining its operational presence in the same regional market.
The most recent analyst rating on (VXRT) stock is a Hold with a $0.37 price target. To see the full list of analyst forecasts on Vaxart stock, see the VXRT Stock Forecast page.
Spark’s Take on VXRT Stock
According to Spark, TipRanks’ AI Analyst, VXRT is a Neutral.
Vaxart’s overall score is primarily influenced by its financial performance challenges, including negative profitability and cash flow issues. The strategic partnership with Dynavax provides a positive outlook, but technical indicators and valuation concerns limit the stock’s attractiveness.
To see Spark’s full report on VXRT stock, click here.
More about Vaxart
Vaxart, Inc. is a biotechnology company that operates in the life sciences sector, with headquarters and laboratory facilities in the South San Francisco, California area. The company occupies multiple offices in this regional biotech hub, reflecting a footprint focused on research and development activities tied to its core biopharmaceutical operations.
Average Trading Volume: 542,006
Technical Sentiment Signal: Strong Sell
Current Market Cap: $83.06M
See more insights into VXRT stock on TipRanks’ Stock Analysis page.